Charles River Laboratories CEVP Shannon Parisotto Sells $302K Under 10b5-1 Plan

Executive Summary

On October 5, 2026, Shannon M. Parisotto, Corporate Executive Vice President of Discovery & Safety Assessment at Charles River Laboratories International, Inc. (NYSE: CRL), executed a standard option exercise and sale transaction. Pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026, Parisotto exercised options to acquire 981 shares of common stock at an exercise price of $208.44 per share and immediately sold all 981 shares at $308.44 per share, realizing gross proceeds of $302,579.64 ($98,100 in gross pre-tax profit spread).

Transaction Details

• Derivative Exercise: Exercised 981 stock options (expiring May 31, 2034) with a strike price of $208.44 per share.
• Open Market Sale: Sold 981 shares of common stock at $308.44 per share under transaction code S.
• Direct Ownership Post-Transaction: 4,807 common shares.
• Indirect Holdings Post-Transaction: 9,680 shares held via Trust and 28,510 shares held via Karpathos Investments LLC, totaling 38,190 indirect shares.
• Remaining Derivative Holdings: 2,944 unexercised stock options.

Market and Trading Context

This transaction carries Low significance for investors due to several key factors:

1. Pre-Established Plan: The transaction was initiated in accordance with a Rule 10b5-1 trading plan established seven months prior (March 4, 2026), mitigating concerns regarding non-public information.
2. Small Position Size: The 981 shares transacted represent a negligible percentage of Parisotto's overall equity footprint, which exceeds 42,000 shares across direct and indirect holdings.
3. Mechanics: The trade functions as a routine compensation monetization and option expiration exercise rather than a discretionary divestment indicating sentiment on company fundamentals.